Advanced Therapy Medicinal Products Market Size, Share, and Trends 2024 to 2034

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis 
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis

Chapter 5. COVID-19 Impact on Advanced Therapy Medicinal Products Market

5.1. COVID-19 Landscape: Advanced Therapy Medicinal Products Industry Impact
5.2. COVID-19 - Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers

Chapter 8. Global Advanced Therapy Medicinal Products Market, By Therapy

8.1. Advanced Therapy Medicinal Products Market Revenue and Volume, by Therapy, 
8.1.1. Gene Therapy
8.1.1.1. Market Revenue and Volume Forecast 
8.1.2. Tissue Engineered Product
8.1.2.1. Market Revenue and Volume Forecast 
8.1.3. Cell Therapy
8.1.3.1. Market Revenue and Volume Forecast

Chapter 9. Global Advanced Therapy Medicinal Products Market, Regional Estimates and Trend Forecast

9.1. North America
9.1.1. Market Revenue and Volume Forecast, by Therapy 
9.1.2. U.S.
9.1.2.1. Market Revenue and Volume Forecast, by Therapy 
9.1.3. Rest of North America
9.1.3.1. Market Revenue and Volume Forecast, by Therapy 
9.2. Europe
9.2.1. Market Revenue and Volume Forecast, by Therapy 
9.2.2. UK
9.2.2.1. Market Revenue and Volume Forecast, by Therapy 
9.2.3. Germany
9.2.3.1. Market Revenue and Volume Forecast, by Therapy 
9.2.4. France
9.2.4.1. Market Revenue and Volume Forecast, by Therapy 
9.2.5. Rest of Europe
9.2.5.1. Market Revenue and Volume Forecast, by Therapy 
9.3. APAC
9.3.1. Market Revenue and Volume Forecast, by Therapy 
9.3.2. India
9.3.2.1. Market Revenue and Volume Forecast, by Therapy 
9.3.3. China
9.3.3.1. Market Revenue and Volume Forecast, by Therapy 
9.3.4. Japan
9.3.4.1. Market Revenue and Volume Forecast, by Therapy 
9.3.5. Rest of APAC
9.3.5.1. Market Revenue and Volume Forecast, by Therapy 
9.4. MEA
9.4.1. Market Revenue and Volume Forecast, by Therapy 
9.4.2. GCC
9.4.2.1. Market Revenue and Volume Forecast, by Therapy 
9.4.3. North Africa
9.4.3.1. Market Revenue and Volume Forecast, by Therapy 
9.4.4. South Africa
9.4.4.1. Market Revenue and Volume Forecast, by Therapy 
9.4.5. Rest of MEA
9.4.5.1. Market Revenue and Volume Forecast, by Therapy 
9.5. Latin America
9.5.1. Market Revenue and Volume Forecast, by Therapy 
9.5.2. Brazil
9.5.2.1. Market Revenue and Volume Forecast, by Therapy 
9.5.3. Rest of LATAM
9.5.3.1. Market Revenue and Volume Forecast, by Therapy

Chapter 10. Company Profiles

10.1. Bluebird Bio, Inc.
10.1.1. Company Overview
10.1.2. Product Offerings
10.1.3. Financial Performance
10.1.4. Recent Initiatives
10.2. Celgene Corporation
10.2.1. Company Overview
10.2.2. Product Offerings
10.2.3. Financial Performance
10.2.4. Recent Initiatives
10.3. Gilead Lifesciences, Inc.
10.3.1. Company Overview
10.3.2. Product Offerings
10.3.3. Financial Performance
10.3.4. Recent Initiatives
10.4. JCR Pharmaceuticals Co., Ltd.
10.4.1. Company Overview
10.4.2. Product Offerings
10.4.3. Financial Performance
10.4.4. Recent Initiatives
10.5. Kolon TissueGene, Inc.
10.5.1. Company Overview
10.5.2. Product Offerings
10.5.3. Financial Performance
10.5.4. Recent Initiatives
10.6. MEDIPOST
10.6.1. Company Overview
10.6.2. Product Offerings
10.6.3. Financial Performance
10.6.4. Recent Initiatives
10.7. Novartis AG
10.7.1. Company Overview
10.7.2. Product Offerings
10.7.3. Financial Performance
10.7.4. Recent Initiatives
10.8. Organogenesis Inc.
10.8.1. Company Overview
10.8.2. Product Offerings
10.8.3. Financial Performance
10.8.4. Recent Initiatives
10.9. PHARMICELL Co., Ltd
10.9.1. Company Overview
10.9.2. Product Offerings
10.9.3. Financial Performance
10.9.4. Recent Initiatives
10.10. Spark Therapeutics, Inc.
10.10.1. Company Overview
10.10.2. Product Offerings
10.10.3. Financial Performance
10.10.4. Recent Initiatives

Chapter 11. Research Methodology

11.1. Primary Research
11.2. Secondary Research
11.3. Assumptions

Chapter 12. Appendix

12.1. About Us
12.2. Glossary of Terms